

## Summary of NICE Guidelines

Title	Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
NICE Reference	TA 223
Date of Review:	July 2018
Date of Publication	May 2011
Summary of Guidance (Max 250 words)	<ul style="list-style-type: none"> <li>• Naftidrofuryl oxalate is recommended as a treatment option for intermittent claudication in people with peripheral arterial disease for whom vasodilator therapy is considered appropriate after taking other treatment options into consideration. Naftidrofuryl oxalate treatment should be started with the least costly licensed preparation.</li> <li>• Cilostazol, pentoxifylline and inositol nicotinate are not recommended for the treatment of intermittent claudication in people with peripheral arterial disease.</li> <li>• People currently receiving Cilostazol, pentoxifylline and inositol nicotinate should have the option to continue treatment until they and their clinicians consider it appropriate to stop.</li> </ul>
Impact on Lab (See below)	<input checked="" type="checkbox"/> None
Lab professionals to be made aware	Not applicable
Please detail the impact of this guideline (Max 150 words)	<p>These guidelines have no impact on the laboratory service provision.</p> <p>The guidelines may optimise the clinical and cost effectiveness of treatment for intermittent claudication in patients with peripheral arterial disease.</p>

### Impact on Lab

- None:** This NICE guideline has no impact on the provision of laboratory services
- Moderate:** This NICE guideline has information that is of relevance to our pathology service and may require review of our current service provision.
- Important:** This NICE guideline is of direct relevance to our pathology service and will have a direct impact on one or more of the services that we currently offer.

**Written by: Sasala Wickramasinghe**  
**Reviewed by: Professor Roy Sherwood**